Dr. Reddys Laboratories Ltd.

Dr Reddy’s lab is currently trading at Rs. 1741.00, up by 2.80 points or 0.16% from its previous closing of Rs. 1738.20 on the BSE.

The scrip opened at Rs. 1750.00 and has touched a high and low of Rs. 1759.00 and Rs. 1721.00 respectively. So far 9460 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 1818.00 on 20-Apr-2012 and a 52 week low of Rs. 1501.00 on 23-Nov-2011.

Last one week high and low of the scrip stood at Rs. 1784.55 and Rs. 1711.60 respectively. The current market cap of the company is Rs. 29443.27 crore.

The promoters holding in the company stood at 25.56% while Institutions and Non-Institutions held 39.75% and 17.76% respectively.

Dr Reddy’s Laboratories, has launched Sildenafil Tablets (20mg), a bioequivalent generic version of REVATIO (Sildenafil) Tablets in the US market on November 16,2012, following the approved by United States Food and Drug Administration (USFDA) of company’s ANDA for Sildenafil Tablets.

Dr Reddy’s Sildenafil Tablets in 20 mg are available in 90 count bottle sizes.

The REVATIO brand has US sales of approximately $338.67 Million for the most twelve months ending September 2012, according to IMS Health.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.